ARCHIVES

ODAC Votes For Accelerated Approval For Adcetris For Two Lymphoma Indications

This article is from The Cancer Letter archive.

Vol. 37 No. 29 | July 22, 2011

Download PDF Visit The Full Archive

Related Articles

Protocols Approved By NCI During January 2004

February 27, 2004

Facilities Survey: $2.5 Billion Will Be Required From 1986-1990, With NCI’s Share At $678 Million

April 12, 1985

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

July 26, 2002

Rhoads Presses For Greater Emphasis On Etiology In DNCP; Workshops Develop New Research Leads

July 16, 1976

NCI-Approved Clinical Trials

November 24, 2006

CIDAC Bids Not Limited To Cancer Research Centers

January 17, 1975